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Excessive signaling by chemokines has been associated with chronic inflammation or cancer, thus 
attracting substantial attention as promising therapeutic targets. Inspired by chemokine-clearing 
molecules shaped by pathogens to escape the immune system, we designed a generic screening 
assay to discover chemokine neutralizing molecules (neutraligands) and unambiguously distinguish 
them from molecules that block the receptor (receptor antagonists). This assay, called TRIC-r, 
combines time-resolved intracellular calcium recordings with pre-incubation of bioactive compounds 
either with the chemokine or the receptor-expressing cells. We describe here the identification of 
high affinity neutraligands of CCL17 and CCL22, two chemokines involved in the Th2-type of lung 
inflammation. The decoy molecules inhibit in vitro CCL17- or CCL22-induced intracellular calcium 
responses, CCR4 endocytosis and human T cell migration. In vivo, they inhibit inflammation in a 
murine model of asthma, in particular the recruitment of eosinophils, dendritic cells and CD4+T cells. 
Altogether, we developed a successful strategy to discover as new class of pharmacological tools to 
potently control cell chemotaxis in vitro and in vivo.
The chemotactic function of chemokines and their receptors is central to tissue development, inflamma-
tion, cancer and metastasis1. It is therefore important to understand and control the chemokine network 
in these diseases. Classic drug development approaches have generated receptor antagonists to modulate 
the chemokine system signaling. This has been proven difficult partly because of the chemokine network 
promiscuity2, but also because receptor antagonists generally have partial agonistic or inverse agonistic 
activities resulting into undesirable effects3. However, pathogens and parasites have developed original 
strategies to circumvent the chemokine system: these organisms express peptides4, soluble proteins5 or 
components mimicking the extracellular matrix6, that all act as decoy molecules and prevent the chemok-
ine binding i) to their cognate receptors, and/or ii) to glycosaminoglycans, thereby collapsing extracel-
lular density gradients and escaping host immune response. In addition, several experimental studies 
report on efficient chemokine neutralization by antibodies7,8, RNA oligonucleotides9, small molecules10 
or decoy receptors11. This rationalizes the concept that chemokine blockade could be an interesting 
strategy to be used as an alternative to conventional receptor blockade. Chemical probes with such neu-
tralizing activity could be useful tools to understand and/or treat chronic inflammation. CCL17 (known 
as Thymus and Activation-Regulated Chemokine, TARC)12 and CCL22 (known as Macrophage-Derived 
Chemokine, MDC)13 represent prominent examples of such effective approach. Both chemokines exert 
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their biological effects through binding to and activating a common receptor, CCR4, which is expressed 
on different cell types, including T helper 2 (Th2) lymphocytes, eosinophils and dendritic cells14. It has 
also been shown that CCL17, CCL22 and CCR4 contribute to the pathogenesis of atopic diseases, like 
asthma and atopic dermatitis (AD)15,16, as the expression of both ligands and their receptor is enhanced 
in asthmatic patients and AD skin lesions17–21. However, the role of CCR4 in atopic diseases is still 
unclear, as some reports show that CCR4-deficient mice develop AD-like symptoms22 and allergic lung 
inflammation23,24 comparable to wild-type mice. However, in a humanized SCID murine model of aller-
gic airway inflammation to House Dust Mite (HDM)14, a CCR4 neutralizing antibody administered prior 
to allergen challenge reduces the allergen-induced inflammation as well as the levels of Th2 cytokines in 
the lungs. In addition, anti-CCL17 and anti-CCL22 neutralizing antibodies25,26 as well as CCL17-deficient 
mice22 suppress airway and cutaneous inflammation. This indicates that there is a potential for molecules 
that could effectively and specifically neutralize CCL17 or CCL22 i) to help understand the role of CCL17 
and/or CCL22, and ii) to develop new therapeutic strategies for allergic diseases.
Here, we develop a generic screening assay to discover small molecules binding to and blocking 
CCL17 and CCL22. We illustrate its potential by identifying i) two selective compounds neutralizing 
CCL17, ii) two selective compounds neutralizing CCL22, and iii) one molecule blocking both chemok-
ines, all found in a collection of natural substances. To this end, we set up a two-step strategy that distin-
guishes, on a kinetic basis, ligands blocking the receptor (receptor antagonists) from those blocking the 
chemokine (neutraligands). A combination of biophysical, biochemical and functional studies was used 
to determine their chemical biological and pharmacological properties, and to show their remarkable 
utility as probes to study inflammatory processes in vitro as well as in vivo in a model of allergic asthma.
Results
Biologically active recombinant chemokines and their receptors. Due to the need for large 
amounts of chemokines both for the screening and the biological studies, we produced CCL17 and 
CCL22. The expression was effective in E. coli BL21 (DE3) using the pET32 construct, which codes for 
the mature CCL17 or CCL22 with an N-terminal thioredoxin-hexahistidin (TRX- (His)6) tag followed 
by an enterokinase cleavage site. SDS-PAGE reveals a band present at 26 kDa for both pET32-CCL17 and 
pET32-CCL22 transfected E.coli in the insoluble fractions « I » (Fig.  1). Few or no fusion chemokine 
was observed in the soluble fractions « S » as well as in the non-induced « NI » samples. The insoluble 
fractions (as inclusion bodies) were solubilized in urea and purified on immobilized metal affinity chro-
matography (IMAC). Most of the chemokine CCL17 or CCL22 was retained on the Ni2+-nitrilotriacetic 
acid column by the (His)6 tag. Fusion chemokines were eluted and then cleaved by enterokinase to sepa-
rate the TRX-His6 from the native functional chemokine (CCL17 or CCL22). Unwanted products (TRX, 
(His)6, uncleaved fusion chemokine, endogenous proteins) were adsorbed on a second IMAC column, 
leaving only pure CCL17 or CCL22 (10 kDa) in the flow-through fractions. HPLC and mass spectrom-
etry analysis revealed that the purified chemokines exhibited the expected molecular weights and had 
retention times identical to those of the commercially available functional chemokines (Supplementary 
Fig. S1).
CCL17 and CCL22 are both agonists of the Gi-protein coupled receptor, CCR4. Their biological activ-
ity was tested in a calcium response assay using Human Kidney Embryonic (HEK) cells over-expressing 
CCR4. We found that both recombinant chemokines induced CCR4-mediated calcium responses at 
37 °C, as shown for CCL17 (Fig. 2a, grey diamonds). These responses were specific to CCR4 expression 
as non-transfected cells that did not express CCR4 did not respond to CCL17 and CCL22.
Recording of chemokine receptor-linked intracellular Ca2+ responses. We established an assay 
based on the recording of intracellular free Ca2+ concentration using an automated system (FlexStation 
3), in order to identify new CCL17 and CCL22 neutraligands. When Gi-coupled calcium responses are 
very small and unreliably measured by the detector, Gqi5-, Gqtop-, Gα 12- or Gα 16-coupling can be 
used to efficiently increase the interaction of Gi-protein coupled receptors to phospholipase C (PLC) 
and intracellular Ca2+ mobilization. In this work, we generated an HEK cell line stably expressing 
EGFP-CCR4, and transiently transfected it with the chimeric Gqi5 protein27. In HEK EGFP-CCR4+ cells, 
the Gqi5 functional expression was confirmed by the measurement of large intracellular Ca2+ responses 
in response to chemokine stimulation, even at 21 °C (Fig. 2a, white circles). EGFP-CCR4+ cells that did 
not express Gqi5, exhibited a typically weak intracellular Ca2+ elevation when recorded at 37 °C (Fig. 2a, 
grey diamonds), and a non-detectable one at 21 °C (Fig. 2a, black circles).
We also evaluated the activity of other chemokines, CCL2 (CCR2 receptor agonist) and CCL5 (CCR1, 
CCR3 and CCR5 agonist)28 on CCR4+ Gqi5+ HEK cells (that do not express CCR2 and CCR5). We 
found that while CCL17 and CCL22 induced calcium fluxes, CCL2 and CCL5 did not. On the other 
hand, HEK cells expressing CCR2 or CCR5 responded, respectively, to CCL2 or CCL5, but not to CCL17 
and CCL22 (data not shown). These results rule out non-specific effects that could occur in this assay.
The EC50 values of calcium responses induced by CCL17 and CCL22 were respectively, 3.7 ± 0.4 and 
2.9 ± 0.5 nM (Fig. 2b,c), identical to those obtained with corresponding commercial chemokines. For fur-
ther studies of the neutraligand inhibitory response, CCL17 and CCL22 concentrations were set at 5 nM.
The parameter describing robustness (Z’)29 of this calcium assay was 0.52 for CCL17 and 0.6 for 
CCL22 screening, allowing the use of this test to screen compound libraries.
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TRIC-r: A generic protocol to identify chemokine neutraligands. Monitoring calcium responses 
in a time-resolved manner allows the discrimination of compounds binding to the chemokine from those 
binding to the receptor. This is achieved using a pre-incubation protocol in which the tested compounds 
are preincubated with the receptor or with the chemokine prior to calcium monitoring. Chalcone 4 (the 
known CXCL12 chemokine neutraligand10) and AMD3100 (a CXCR4 chemokine receptor antagonist30) 
were both tested in these protocols in order to illustrate the approach, using EGFP-CXCR4+ HEK cells 
and recombinant CXCL12. When chalcone 4 was preincubated with the chemokine ([CK + N], Fig. 2d) 
before addition to CXCR4-expressing cells, the amplitude of calcium responses was smaller than when 
chalcone 4 was preincubated with the receptor ([R + N], Fig. 2d), i.e. CXCR4-expressing cells, prior to 
chemokine (CK) addition. By contrast, when the CXCR4 antagonist (AMD3100) was preincubated with 
CXCL12 ([CK + A], Fig.  2e) before addition to the cells, the amplitude of Ca2+ responses was much 
greater than when preincubated with the receptor ([R + A], Fig. 2e) prior to chemokine (CK) addition. 
These incubation protocols are named Time-Resolved Intracellular Calcium recordings (TRIC-r) allow-
ing the identification of neutraligands versus receptor antagonists. The validity of the “TRIC-r” method 
here demonstrated allows an extension to a general concept of search for chemokine neutraligands.
Automated screening of chemokine neutraligands. The functional screening assay was run on 
a collection of c.a. 480 very diverse and natural molecules from the GreenPharma’s library (described 
in Supplementary Table S1). The chemicals were preincubated with CCL17 or CCL22 (neutraligand 
protocol) for 1 h prior to addition to the CCR4+cell suspension. Figure  3 shows hit compounds that 
Figure 1. Production and purification of recombinant human CCL22 and CCL17. (a) E. coli BL21 
(DE3) cells were transformed with pET32-TRX-(His)6-CCL17 or pET32-TRX-(His)6-CCL22 expression 
vectors. Cultures (1 ml) were collected and saved for SDS-PAGE (12%) analysis (lanes 2 and 5). Then, the 
production of TRX-(His)6 fusion CCL17 and CCL22 was induced by isopropyl-β -D-thiogalactopyranoside 
(IPTG) (lanes 3, 4, 6 and 7). « S » and « I » refer to the soluble (lanes 3 and 6) and insoluble (lanes 4 and 7) 
fractions, respectively. « NI » refers to the non-induced protein fraction (lanes 2 and 5). Lane 1: molecular 
weight standards. The arrow indicates the expected fused CCL17 or CCL22 band at ≈ 26 kDa corresponding 
to CCL17 or CCL22 + TRX + (His)6. (b) Purification steps of the human CCL22 on Ni2+-nitrilotriacetic 
acid (Ni-NTA) column. Samples from the « washing steps » were analysed on a 12% SDS-PAGE. Lane 
1: molecular weight standards. Lane 2: non-induced fraction “NI”. Lane 3: soluble fraction “S”. Lane 4: 
insoluble fraction “I”. Lane 5: flow-through after incubating the insoluble fraction with the column. Lane 6: 
flow-through after denaturation. Lane 7: flow-through after β -cyclodextrin lavage. Lane 8: flow-through after 
oxidation. Lane 9: peak fractions eluted with imidazole. (c) Samples from enterokinase-digested chemokines 
were analysed on a 20% SDS-PAGE. Lane 1: molecular weight standards. Lanes 2 and 3: CCL22 and CCL17 
flow-through fractions after enterokinase digestion and a second round Ni-NTA. CK: chemokine; (His)6: 
hexahistidin; TRX: thioredoxin.
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reduce by more than 20% (2 × SD of control chemokine calcium responses) the amplitude of CCL17- 
and CCL22-calcium responses (white bars). For CCL17, the most active compounds, GPN279 and 
GPN251 (2 μ g/ml), inhibited CCL17-induced calcium responses by 42 and 53%, respectively (Fig. 3a,c). 
For CCL22, GPN136 and GPN025 (2 μ g/ml) blocked calcium responses by 46 and 44%, respectively 
(Fig. 3b,c). One compound, GPN355 (2 μ g/ml) blocked both CCL17 and CCL22 calcium responses by 
42 and 100%, respectively (Fig.  3a–c). None of the hit compounds did antagonize the CCR4 receptor, 
i.e. their preincubation with the receptor-expressing cells for 1 h did not affect the response to CCL17 
or CCL22 (Fig.  3a,b, grey bars). Conversely, the CCR4 antagonist, C-02131, abolished responses when 
preincubated with the receptor, but not with the chemokine.
These five hit compounds were resynthesized and their dose-response curves were performed in the 
calcium assay. The IC50 values for CCL17 neutralization were 0.9 ± 0.1 μ M for GPN251, 7.1 ± 1.7 μ M 
for GPN279 and 9.6 ± 0.9 μ M for GPN355 (Fig.  3d). The IC50 values for CCL22 neutralization were 
10.6 ± 3.7 μ M for GPN025, 11.6 ± 2.5 μ M for GPN136, and 0.2 ± 0.0 μ M for GPN355 (Fig. 3e).
Solubility studies showed that GPN279, GPN136, GPN025 and GPN355 were soluble (solubility 
> 10 μ M) in HEPES buffer and in the cell culture medium. By contrast, GPN251 had a limited solubility 
in HEPES buffer (0.7 μ M) and was not detected as a free molecule in the culture medium. We therefore 
Figure 2. Functional assay to identify chemokine neutraligands. (a) Functional expression of Gqi5 in 
EGFP-CCR4-expressing HEK cells. Intracellular calcium responses were recorded after stimulation with 
5 nM CCL17 (at t = 50 s) in EGFP-CCR4+HEK cells transfected with Gqi5 () at 21 °C. Gqi5-non transfected 
EGFP-CCR4+HEK cells were used as controls at 37 °C (◆) and 21 °C (•). Dose-response curves of CCL17 
(b) and CCL22 (c)-induced calcium responses were performed in EGFP-CCR4+Gqi5+ HEK cells at 21 °C. 
Data represent the means ± SD of three independent experiments. (d) “Neutraligand” TRIC-r protocol. 
The identification of neutraligands relies on the measurement of kinetic-based calcium responses. To prove 
this concept, we used chalcone 4, a fully validated CXCL12 neutraligand. After stimulation with CXCL12 
(at t = 60 s), EGFP-CXCR4+ HEK cells exhibited calcium responses (solid black line). When chalcone 4 
was preincubated with CXCL12 for 1 h before addition to the cells (dotted black line), the amplitude of 
calcium responses was smaller than when the neutraligand was preincubated with the receptor, prior to 
chemokine addition (solid grey line). (e) “Antagonist” TRIC-r protocol. After stimulation with CXCL12 
(at t = 90 s), EGFP-CXCR4+ HEK cells exhibited calcium responses (solid black line). When the CXCR4 
antagonist (AMD3100) was preincubated with CXCL12 (solid grey line) for 1 h before addition to the cells, 
the amplitude of calcium responses was much greater than when the antagonist was preincubated with the 
receptor prior to chemokine addition (dotted black line). A: antagonist; CK: chemokine; N: neutraligand; R: 
receptor; the preincubation mixture is given in brackets. a.u.; arbitrary unit.
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discarded GPN251 from further experiments, and continued the pharmacological characterization of 
the other compounds.
The cytotoxicity of GPN279, GPN136, GPN025 and GPN355 was assessed on human HUT78 T cells 
after 72 h of culture by measuring cell metabolic activity (Supplementary Fig. S2). The level of metabolic 
activity of cells treated with GPN279 or GPN136 at the highest concentration (30 μ M) was similar to 
that of control non-treated cells, indicating no cytotoxic activity. GPN355 induced a 23.1% inhibition of 
HUT78 cell metabolic activity at 30 μ M. In addition, a significant concentration-dependent inhibition 
of HUT78 cell metabolic activity was observed in the presence of GPN025 (81.3% inhibition at 30 μ M), 
definitely confirming that GPN025 impairs HUT78 cell viability. Similar data were obtained for the 
human epidermal HaCat cells. Cytotoxicity of the active molecules was also tested on human monocytes 
in culture (Supplementary Fig. S3) using the Alamar Blue method. This confirmed the absence of cell 
toxicity of GPN136 and GPN279 up to 250 μ M. Following these experiments, GPN025 and GPN355 were 
discarded from further investigations.
Biophysical characterization of neutraligand binding. The tryptophan fluorescence technique 
can be used to study protein-ligand interactions since chemokines contain tryptophan residues. Several 
reports show that, upon binding to a protein containing tryptophan residues, the ligand modulates 
its intrinsic fluorescence10. The molecule might directly interact with the tryptophan, or bind to a site 
allowing protein conformational changes or modify tryptophan microenvironment, leading to altered 
Figure 3. Identification of chemokine neutraligands. Compounds exhibiting a neutraligand activity, 
are screened on calcium responses induced by chemokines in the “neutraligand protocol”, i.e. drugs 
preincubated with CCL17 (a) or CCL22 (b) (5 nM, white bars) and in the “antagonist protocol” (grey bars). 
Results of the primary screen are expressed in percentage for compounds tested at a concentration of 2 μ g/
ml. C-021, the CCR4 receptor antagonist, was used as a control in both “neutraligand” and “antagonist” 
protocols. Molecules were considered as hits when the percentage was under 2 × SD of calcium responses 
induced by the chemokine alone. (c) Chemical structures of the 5 hit compounds. GPN251 is (Z)-4-
benzylidene-2-(3,4,5-trimethoxyphenyl)oxazol-5(4H)-one. GPN279 is 1,3-dimethyl-7-(3-methylbut-2-
enyl)-1H-purine-2,6(3H, 7H)-dione. GPN136 is 2,3-dihydroxypropyl 2-hydroxybenzoate. GPN355 is 
4a-hydroxy-6,8-dimethyl-6,8-dihydropyrimido[5, 4-e][1, 2, 4]triazine-5,7(2H, 4aH)-dione. GPN025 is 
(R)-1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)propan-1-one. (d) Inhibition of CCL17-induced calcium 
mobilization by GPN251, GPN279 and GPN355 neutraligands. CCL17 (5 nM) was preincubated with 
increasing concentrations of GPN251 (◆), GPN279 () or GPN355 (■) 1 h prior to addition to the EGFP-
CCR4+Gqi5+ HEK cells. (e) Inhibition of CCL22-induced calcium mobilization by GPN025, GPN136 and 
GPN355. CCL22 (5 nM) was preincubated with increasing concentrations of GPN025 (•), GPN136 (◊) or 
GPN355 (■) 1 h prior to addition to EGFP-CCR4+Gqi5+ HEK cells. CCR4+Gqi5+ HEK cells were loaded 
with the calcium-sensitive dye indo-1 AM; fluorescence intensity emitted at 401 nm and 475 nm in response 
to excitation at 355 nm was recorded at 21 °C. Results were analyzed by fitting the experimental curves 
using the Kaleidagraph software program, and the corresponding IC50 values were calculated. Means and SD 
values of triplicates were plotted.
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tryptophan fluorescence. Here, we determine the fluorescence of CCL17 or CCL22 alone upon excita-
tion of tryptophan residues at 285 nm, and detect fluorescence emission with a peak (at 340 nm) that 
does not show any spectral shift in the experimental conditions tested. When a fixed amount of CCL17 
or CCL22 (1.5 μ M) is mixed with a neutraligand (GPN279 for CCL17 and GPN136 for CCL22), a 
concentration-dependent decrease in tryptophan fluorescence is detected at 340 nm, reflecting binding 
of neutraligands to their corresponding chemokine (Fig.  4). No significant change in tryptophan fluo-
rescence was observed with the CCR4 antagonist C-021, consistent with its lack of binding to CCL17 
or CCL22. The biphasic behavior of the titration curves (discontinuity at approximately 1 μ M ligand) 
reflects the neutraligand binding to two independent sites with each interaction producing changes in 
tryptophan fluorescence intensity. The binding affinity values (KD) of neutraligands for their respective 
chemokines were determined using a second order equation that was fully consistent as shown by the fit, 
with two categories of sites with low- and high-affinities. KD values for the high-affinity binding site class 
were estimated as below 50.0 nM for the GPN279 and GPN136. KD values for the low-affinity binding 
site class were 57.0 μ M for GPN279 on CCL17 and 53.0 μ M for GPN136 on CCL22.
Identification of CCL17 and CCL22 residues that allow interaction with the neutraligands. In 
order to investigate the possible binding sites for GPN compounds on CCL17 and CCL22, we docked 
these ligands onto 3D structure models. CCL17 3D structure is known32 and that of CCL22 (which 
has not yet been solved) was elaborated on the basis that CCL17 and CCL22 share important sequence 
homologies (67% of homology) and both activate the same CCR4 receptor. As could be expected from 
tryptophan fluorescence studies, docking experiments revealed more than one possible interaction, sug-
gesting the existence of two binding sites on CCL17 and CCL22. In the models, Ser74, Asn78 and Arg80 
(Fig. 5a-1) from CCL17 represent plausible attachment points for GPN279, while in CCL22, a binding 
site for GPN136 is delineated by Trp55, Thr56, Asp58 and Arg80 (Fig. 5a-2).
Figure 4. Quenching of the intrinsic tryptophan fluorescence of CCL17 and CCL22 by hit molecules. 
CCL17 and CCL22 were titrated with increasing concentrations (0–25 μ M) of GPN279 (a,) or GPN136 
(b,☐), respectively, and the change in tryptophan fluorescence was monitored as a function of the added 
ligand. As a control, the CCR4 antagonist, C-021, was tested on CCL17 (c,•) and CCL22 (d,■). The 
fluorescence emission spectrum (300–400 nm) of each sample was measured at an excitation wavelength of 
285 nm. The fluorescence emission spectra were corrected by subtracting the emission scan of the compound 
alone. DMSO had no effect on the fluorescence measurements. Titration data were normalized by dividing 
the measured fluorescence (F) by the initial fluorescence in the absence of the compound (F0) at 340 nm. 
Solid lines show the fit of the data to a second order equation: (RL)2 + (RL) × (-Ro-Lo-KD) + Ro × Lo = 0 
where (RL) = ((Ro + Lo + KD) ± ((-Ro-Lo-KD)2-4 × Ro × Lo)1/2)/2 and where Ro, the concentration of 
CCL17 or CCL22 was set at 1.5 μ M; Lo is the initial concentration of the neutraligand; KD is the dissociation 
constant of the neutraligand for the chemokine; and RL is the fractional concentration of chemokine and 
ligand complex. Data are means (dots) and bars are SD values of three independent experiments.
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To parse the contributions of these amino acids to binding of GPN279 and GPN136 binding, we 
expressed seven chemokine mutants, in which the residues Ser74, Asn78, Arg80 from CCL17, and Trp55, 
Thr56, Asp58 and Arg80 from CCL22 were substituted by Ala, Val, Trp, Ala, Ala, Ala and Asn, respec-
tively. CCL17 and CCL22 mutants (5 nM) induced calcium responses similar to those of WT counter-
parts (Fig.  5b). On CCL17 S74A, GPN279 no longer acted as a neutralizing molecule. CCL17 N78V 
was less sensitive than WT to GPN279 (75.0 ± 6.0% instead of 56.0 ± 5.0% calcium response for WT 
CCL17), and CCL17 R80W was inhibited by GPN279 similarly to WT CCL17 (50.0 ± 11.0% compared 
to 56.0 ± 5.0%). On the same CCL17 mutants, GPN136 was totally ineffective, as expected from the 
absence of interaction with this chemokine. For CCL22, GPN136 no longer inhibited calcium responses 
induced by CCL22 R80N (100.0 ± 3.0% compared to 46.0 ± 6.0% for WT CCL22), and to a lower extent 
those induced by CCL22 D58A (76.0 ± 3.0%). However, GPN136 inhibited CCL22 T56A (40.0 ± 6.0%) 
and CCL22 W55A (46.0 ± 3.0%)-induced calcium responses similarly to CCL22 WT. GPN279 neither 
inhibited WT nor CCL22 mutants, confirming that this compound does not bind to CCL22. Taken 
together, these findings strengthen our view that Ser74 and Asn78 (in CCL17) as well as Arg80 and 
Asp58 (in CCL22) are likely involved in physical contacts with GPN279 and GPN136, respectively, and 
constitute an essential part of CCL17 and CCL22-binding sites. Noteworthy, these predicted binding sites 
were found in geographically distinct regions in CCL17 and CCL22.
Generalization of TRIC-r assay for selectivity profiling. The selectivity of the neutraligands was 
evaluated on 10 different chemokines belonging to the CC and CXC subfamilies in both the neutrali-
gand and incubation protocols. Consistent with data from Fig. 6a, GPN279 (10 μ M) inhibited by 40.0% 
the CCL17-evoked calcium responses in EGFP-CCR4+HEK cells, whereas it had no effect on calcium 
responses induced by CCL3, CCL4, CCL5, CCL22, CXCL8, CXCL10, CXCL11 and CXCL12 chemok-
ines on their respective receptors (grey bars). GPN136 (10 μ M) inhibited 46.0% of the CCL22-evoked 
calcium responses in HEK EGFP-CCR4+cells, and had no effect on calcium responses induced by any 
other chemokine (white bars). GPN279 is therefore a selective CCL17 neutraligand, and GPN136 a 
selective neutraligand of CCL22. None of these compounds had any effect on calcium responses when 
preincubated with the receptors, i.e. in the “antagonist” protocol (data not shown).
In vitro activity of chemokine neutraligands. We investigated the ability of neutraligands to 
inhibit CCL17 and CCL22-evoked CCR4 internalization. Receptor endocytosis was monitored on 
EGFP-CCR4+HEK cells and was quantified by flow cytometry. Confirming previous observations33–35, 
CCL22 induced marked CCR4 internalization (78.0 ± 3.0%), whereas CCL17 was less potent and induced 
approximately 43.0 ± 3.0% of receptor endocytosis at the same concentration (100 nM). Figure  6b 
shows that GPN279 inhibited CCL17-mediated CCR4 internalization in a concentration-dependent 
Figure 5. (a) In silico modeling of GPN279 and GPN136 binding to respectively CCL17 and CCL22. 
GPN279 docking (a1) highlights interaction with CCL17 Ser74, Asn78, and Arg80. GPN136 docking (a2) 
shows interaction with Asp58, Thr56, Trp55, Arg80 residues. (b) Effect of DMSO (black bars), GPN279 
(10 μ M, grey bars) and GPN136 (10 μ M, white bars) on calcium responses induced by CCL17 and CCL22 
mutants (5 nM). *p < 0.05; **p < 0.01 as compared to WT chemokine preincubated with the neutraligand.
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manner (0.03–3 μ M) with half-maximal efficiency around 0.2 μ M. GPN136, dose-dependently, reduced 
CCL22-induced internalization with half-maximal efficiency in the 0.1 μ M range. Neither GPN279 nor 
GPN136 did alter CCR4 receptor surface level on its own (data not shown).
We next analyzed the effect of neutraligands on the chemotactic activity of CCL17 and CCL22 on 
human HUT78 T cells that endogenously express CCR4 receptor34–36. Confirming previous reports34, 
we observed that CCL17 and CCL22 induced HUT78 cell migration with a bell-shaped dose-response 
curve. For further studies of the neutraligand inhibitory response, CCL17 and CCL22 concentrations 
were set at 3 nM. GPN279 induced a concentration-dependent inhibition of the chemotactic response 
with an IC50 = 0.15 ± 0.01 nM (Fig.  6c) when preincubated for 1 h with CCL17. GPN136 also showed 
high potency in inhibiting CCL22-induced chemotaxis (IC50 = 0.34 ± 0.1 nM). Importantly, the absence 
of effects of the neutraligands by themselves indicates that they are devoid of chemotactic activity 
(Supplementary Fig. S4). This assay also reveals a drastic migration difference depending on the incu-
bation protocol. Indeed, when the neutraligands were preincubated with the cells, as in the receptor 
Figure 6. (a) Selectivity of CCL17 and CCL22 neutraligands towards 10 chemokines according to the 
“neutraligand protocol”. Inhibition by DMSO (black bars), GPN279 (grey bars) and GPN136 (white bars) 
(10 μ M) of calcium responses triggered by either 5 nM CCL2 on EGFP-CCR2+ HEK cells, by 5 nM CCL3, 
CCL4 and CCL5 on EGFP-CCR5+ HEK cells, by 5 nM CCL17 and CCL22 on EGFP-CCR4+ HEK cells, 
by 5 nM CXCL8 on EGFP-CXCR2+ HEK cells, by 5 nM CXCL10 and CXCL11 on EGFP-CXCR3+ HEK 
cells, or by 5 nM CXCL12 on EGFP-CXCR4+ HEK cells. Each column represents the mean (block) ± SD 
(bars) of n = 3 experiments performed in triplicate. *p < 0.05; **p < 0.01; ***p < 0.005 as compared to 
chemokine + DMSO. (b) Chemokine neutraligands inhibited CCR4 endocytosis induced by CCL22 or 
CCL17. EGFP-CCR4+ HEK cells were incubated for 30 min with DMSO or chemokine (100 nM CCL22 or 
CCL17) in the presence or absence of test compounds. GPN279 and GPN136 were applied at concentrations 
of 0 μ M (dark grey bars), 0.03 μ M (light grey bars), 0.3 μ M (white bars), and 3 μ M (stripped bars). Cell 
surface EGFP-tagged CCR4 receptors were measured by EGFP antibody labeling and flow cytometry 
analysis. CCR4 internalization was expressed as a percentage of total receptor surface expression calculated 
using control cells incubated with DMSO (100%). Each column represents the mean (block) ± SD (bars) 
of n = 3 experiments performed in triplicate. *p < 0.05; **p < 0.01; ***p < 0.005 as compared to chemokine 
alone. (c,d) Inhibition of CCL17 and CCL22- induced CCR4+HUT78 T cell chemotaxis by neutraligands. 
Human CCR4+HUT78 cells were induced to migrate in the Transwell plates, where 3 nM CCL17 or CCL22 
pre-incubated either with DMSO (◆) or increasing concentrations of neutraligands (GPN279 () for 
CCL17 and GPN136 () for CCL22) at room temperature for 1 h, and then loaded in the lower chamber. 
The number of migrating cells induced by a chemokine alone was set at 100% migration. The number 
of migrating cells in the presence of chemokine and compounds were expressed as the corresponding 
percentages. Results were analyzed by fitting the experimental curves (% of migrating cells vs log compound 
concentration) using the Kaleidagraph software program, and the corresponding IC50 values were calculated. 
Means and SD values of triplicates were plotted.
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antagonist protocol, they show no ability to inhibit CCR4+ HUT78 cell chemotaxis, whereas the specific 
CCR4 antagonist, C-021 (1 μ M), inhibited 90% of T cell migration (Supplementary Fig. S4).
We also analyzed the consequences of CCL17 and CCL22 blockade on the migration of human kerati-
nocyte HaCat cells that constitutively express CCR437 in a “scratch wound” assay (Supplementary Fig. S5). 
While complete wound closure of scratches was seen after 72 h of treatment of HaCat cells with CCL17 
and CCL22, we found that GPN279 and GPN136 (10 μ M) inhibited CCL17 and CCL22-mediated wound 
closure by 81.4 and 85.2%, respectively.
GPN279 and GPN136 exhibit close structural similarity with respectively, theophylline38 (phos-
phodiesterase inhibitor) and aspirin (cyclooxygenase (COX) 1 inhibitor)39, which are known as 
anti-inflammatory agents. We therefore evaluated the activity of theophylline, aspirin and their derivatives 
(Supplementary Table S2) on CCL17- and CCL22-induced calcium responses. In contrast to GPN279 
(compound 1) and GPN136 (compound 6), theophylline (compound 2) and aspirin (compound 13) had 
no effect on calcium responses (0.0% inhibition at 5 μ M) induced by CCL17 or CCL22, respectively. We 
also found that GPN279 had no effect on COX1 and COX2 activity, and that GPN136 inhibited COX1 
activity but only at high doses (> 100 μ M) (Supplementary Fig. S3). In summary, GPN279 (selective for 
CCL17) and GPN136 (selective for CCL22) at concentrations below 100 μ M exhibit anti-inflammatory 
activity with a mechanism that differs from that of theophylline and aspirin.
In vivo activity of chemokine neutraligands. Both CCL17 and CCL22 have been reported to partic-
ipate into the development of asthma40. Our aim was therefore to validate the activity of our compounds 
in a murine model of asthma. Before doing so, we validated the neutraligand activity of GPN279 and 
GPN136 on calcium responses induced by the murine isoforms of CCL17 and CCL22. GPN279 inhib-
ited mouse CCL17-evoked calcium signaling with IC50 = 5.2 ± 0.9 μ M, and GPN136 inhibited mouse 
CCL22-evoked calcium responses with IC50 = 8.1 ± 1.5 μ M (Supplementary Fig. S6), results similar to 
the IC50 values of human isoforms. We thereby confirm that GPN279 and GPN136 neutralize mouse and 
human CCL17 and CCL22, respectively, and may be used in a murine model of airway allergic hypere-
osinophilic inflammation. Mice were sensitized to- and challenged with- ovalbumin (OVA) in order to 
develop airway inflammation, and inflammatory parameters were measured in the absence and presence 
of GPN279 or GPN136. In this in vivo model of allergic asthma, increased inflammatory cell numbers 
were found in the bronchoalveolar lavage fluid (BALF). We detected in particular a massive recruitment 
of eosinophils (18.0 ± 1.1 × 105) together with neutrophils (1.1 ± 0.1 × 105), CD11c+ F4/80+macrophages 
(2.1 ± 0.2 × 105), CD3+T cells (2.6 ± 0.1 × 105), CD4+T cells (1.4 ± 0.1 × 105) and CD11c+F4/80−dendritic 
cells (6.4 ± 0.3 × 103) (Fig. 7). Systemic treatment (I.P.) with GPN279 or GPN136 (350 μ mol/kg) signif-
icantly reduced the overall number of inflammatory cells, in particular of recruited eosinophils, T cells 
and CD4+T cells, and CD11c+F4/80− dendritic cells, as compared with vehicle-treated mice (Fig.  7). 
While GPN279 significantly inhibited the neutrophil counts in BALF of OVA-treated mice, GPN136 did 
not. The number of CD11c+F4/80+macrophages was not modified in GPN279- and GPN136-treated 
mice compared to vehicle-treated mice. Taken together, these data strongly confirm that the decoy mol-
ecules GPN279 and GPN136 neutralizing CCL17 and CCL22, respectively, have an inhibitory effect in 
our in vivo model of allergic asthma, showing anti-inflammatory activity by reducing the accumulation 
of eosinophils, dendritic cells and CD4+T cells in the airways.
Discussion
Emergence of targeted therapies has markedly improved the management of atopic disorders. However, 
treatment options for the most insidious forms of these diseases, characterized by therapeutic resistance, 
remain elusive. Recently, the signaling axis formed by chemokines and their receptors has been attrib-
uted a causal role in the development of atopic diseases, highlighting new opportunities for therapeu-
tic intervention. A number of strategies have been pursued to develop chemokine receptor inhibitors, 
including antibodies or small molecules to block receptor signaling (antagonists). Despite these efforts, 
current anti-chemokine receptor therapeutics either show modest anti-inflammatory activity, or induce 
substantial off-target effects2,41.
Our current study shows that the novel neutraligand strategy makes the development of chemokine 
inhibitors a new challenging issue. Neutraligands mimic the naturally occurring decoy proteins encoded 
by pathogens to prevent the host inflammatory response42,43. They constitute therefore interesting tools 
to be added to the traditional antagonist panoply.
Toward the discovery of chemokine neutraligands, we designed a generic screening assay, which is 
called “Time-Resolved Intracellular Calcium recording” (TRIC-r). This functional screening is based on 
the kinetic measurement of chemokines-induced calcium responses. Depending on the mode of com-
pound library preincubation either with the chemokine or with the receptor, the TRIC-r method allows 
a rapid and efficient identification of bioactive molecules and unambiguously identifies the target as 
being either the receptor or the chemokine itself. Our results validate TRIC-r as a fast, quantitative 
and sensitive technique that requires reasonably low amounts of biological materials and chemicals, 
and avoids selecting molecules that would bind to the cytokine without neutralizing its function. Even 
though it uses a calcium indicator, TRIC-r can be considered as a label-free technology since neither the 
receptor nor the chemokine need to be chemically or genetically modified. This makes TRIC-r easy to 
set-up and to apply to several chemokine-chemokine receptor pairs from CC- and CXC subfamilies, as 
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illustrated here for ten of them. This could also allow the identification of neutraligands for chemokines 
such as CXCL1444 or CXCL1545, which have no identified receptor yet, provided that we can find cells 
responding to these chemokines.
Application of the TRIC-r assay to CCL1712 and CCL2213 led to the discovery of 5 structurally unre-
lated neutraligands, namely GPN279 and GPN251 for CCL17, GPN136 and GPN025 for CCL22, and 
GPN355 that targets both chemokines. Out of these molecules, GPN279 and GPN136 directly interact 
with chemokines, as assessed by tryptophan fluorescence alterations and by site directed mutagenesis, 
and thereby block cellular responses induced by chemokines, i.e. calcium responses, HUT78 chemotaxis, 
HaCat migration, and CCR4 receptor endocytosis.
In contrast to receptor antagonists, neutraligands do not affect the basal activity level of chemokine 
receptors. As do most G-protein coupled receptors, chemokine receptors exhibit constitutive activity. 
Pharmacological agents interacting with these receptors display a broad spectrum of activities, ranging 
from full agonists through partial and biased agonists to full antagonists (inverse agonists)3. Very few of 
them bind to the receptor without modifying the basal activity. Therefore, antagonists generally interfere 
with cell homeostasis, an effect that is absent when the chemokine itself is neutralized with antibodies or 
neutraligands46. Indeed, in the present study, the neutraligands by their own did not alter the basal level 
of CCR4-associated responses. This constitutes an important result since it had previously been reported 
that some CCR4 antagonists could act as agonists for cell chemotaxis35,47.
In addition, a recent report34 suggested that CCL17 and CCL22 bind to distinct CCR4 receptor confor-
mations on leukocytes, resulting in blockade of signaling via one conformation but not the other. These 
findings represented a potential caveat against the development of CCR4 antagonists. Neutraligands may 
therefore be a rescue to target the CCR4 pathway.
We here propose a well-structured binding pocket for GPN136 on CCL22, and for GPN279 on 
CCL17, with interactions of the neutraligands with chemokine amino-acid residues. These have been 
evaluated by site-directed mutagenesis of Ser74, Asn78 residues in CCL17 and Arg80 and Asp58 in 
CCL22 preventing GPN279 and GPN136 to inhibit calcium responses, and demonstrating the validity 
of our proposed model.
We showed that GPN279 and GPN136 inhibit calcium responses induced by murine CCL17 and 
CCL22 isoforms, respectively, as efficiently as they block human chemokines. These findings are con-
sistent with the notion that binding pockets are similar on human and mouse chemokine isoforms. In 
agreement, human and murine CCL22 isoforms share three identical residues (Trp55, Thr56, and Arg80) 
in their binding sites. Similarly, human CCL17 exhibits two residues (Asn78, Arg80) similar to those of 
Figure 7. Effect of the CCL17 neutraligand (GPN279) and of the CCL22 neutraligand (GPN136) on 
the inflammatory cell infiltration in the bronchoalveolar lavage (BAL) in a mouse model of allergic 
eosinophilic airway inflammation. Balb/c mice were sensitized (i.p.) to OVA and challenged (i.n.) with 
OVA or saline in mice treated with solvent (black), GPN136 (white) or GPN279 (grey) administrated 
intraperitoneally (350 μ mol/kg). The differential number of cells recovered in BAL fluid 24 h after the 
last challenge was counted by flow cytometry. Live leukocytes were identified as CD45+DAPI− cells then 
differentiated into T cells (CD11blowCD19−CD3+), CD4+T cells (CD11blowCD19−CD3+CD4+), eosinophils 
(CD11b+CD11c−GR1−), neutrophils (CD11b+CD11c−GR1+), macrophages (CD11b+GR1−CD11c+F4/80+), 
dendritic cells (CD11b+GR1−CD11c+F4/80−).
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the murine isoform (Asp78, His80). On the other hand, we notice that the negatively charged Asp58 in 
human CCL22 is replaced by a positively charged Lys58 in the mouse isoform, and that a polar Ser74 
in human CCL17 is replaced by an apolar alanine residue in the mouse isoform. In silico modeling of 
the binding area indeed shows that amino acids surrounding the binding site are likely to exert com-
pensatory effects, thereby accounting for the identical efficacy of GPN136 and GPN279 on human and 
mouse chemokines.
Since CCL17 and CCL22 are involved in the pathogenesis of atopic diseases, we finally studied the 
in vivo activity of GPN279 and GPN136 at inhibiting inflammatory cell recruitment in a mouse model 
of allergic asthma. Our data show reduction of eosinophil, CD4+T cell and dendritic cell counts by each 
neutraligand, reinforcing previous results upon treatment with CCL1725,26 or CCL2225 neutralizing anti-
bodies in models of allergic airway inflammation.
In conclusion, we here describe a generic assay to identify neutraligands and demonstrate that 
chemokine neutralization offers a judicious approach for therapeutic intervention. Notably, the decoy 
GPN279 and GPN136 molecules validate CCL17 and CCL22 as therapeutic targets in allergy and create 
a path for its potential to be realized.
Methods
Reagents. The GreenPharma’s library (480 compounds, 2 mg/ml) was prepared in 96-well plates 
(Supplementary Table S1). GPN279 (purity > 95%), GPN251 (purity > 95%), GPN136 (purity > 95%), 
GPN025 (purity > 80%) and GPN355 (purity > 90%) were synthesized by GreenPharma, and their 
structural identity was confirmed by mass spectrometry and 1H NMR analysis. C-021 and AMD3100 
were purchased from Calbiochem. Human recombinant chemokines (CCL5, CCL17, CCL22, CXCL8, 
CXCL10, CXCL11 and CXCL12) were produced in E.coli BL21 (DE3), refolded and purified using 
Ni-NTA chromatography. The protocol is detailed in Supplementary material. Human CCL2, CCL3 and 
CCL4 and mouse CCL17 and CCL22 were purchased from R&D systems.
Generation of HEK-293 cells stably expressing human chemokine receptors. Human cDNAs 
encoding CCR4 and CXCR3 receptors were cloned in pIRES plasmid (Clontech) while cDNAs encoding 
CCR2, CCR5, CXCR2 and CXCR4 receptors were cloned in pCEP4 vector (Life technologies). The recep-
tors are cloned in frame with a signal peptide fused to enhanced green fluorescent protein (EGFP) as 
described previously48. All plasmid constructs were fully sequenced prior to transfections. Human Kidney 
Embryonic HEK-293 cells (ATCC) were maintained in Minimal Essential Medium (MEM, Invitrogen) 
supplemented with 10% FCS, penicillin (100 U/ml), streptomycin (100 μ g/ml) and L-glutamine (2 mM) 
(Invitrogen) at 37 °C and 5% CO2. The cells were transfected with pIRES EGFP-CCR4 plasmid using 
calcium phosphate precipitation method. Stably EGFP-CCR4+ HEK cells were selected for 5 weeks with 
geneticin (G-418, 600μ g/ml), and resulting cell clones were checked by fluorescence microscopy and 
FACS analysis. HEK cells stably expressing human CXCR2, CXCR3, CXCR4, CCR5 and CCR2 were 
generated as described previously10.
Construction of a cell line co-expressing Gqi5 and CCR4. Human Gqi5 cDNA was produced 
by PCR-based site-directed mutagenesis of the last 5 amino acids of Gq into Gi using the forward 
primer 5′ -CCTCCAGTTGAACCTGAAGGACTGCGGCCTCTTCTAACTCGAGTCTAGAGGGC-3′ 
and the reverse primer 3′ -GCCCTCTAGACTCGAGTTAGAAGAGGCCGCAGTCCTTCAGGTTCAA- 
CTGGAGG-5′ . Gqi5 cDNA was cloned into pcDNA 3.1 plasmid (Invitrogen) by overlap extension 
method. EGFP-CCR4-HEK cells were transiently transfected with the plasmid encoding Gqi5. The 
experiments were carried out 24 h after transfection to allow for Gqi5 protein expression.
Calcium assay. Cell plate preparation. EGFP-CCR4+Gqi5+HEKcells were loaded with fluorescent 
Ca2+-indicator Indo-1 AM (5μ M, Interchim) for 45 min at 37 °C. The cells were detached in PBS-EDTA 
(5 mM) for 2 min, suspended in growth medium, pelleted by centrifugation at 320 × g for 5 min, and 
resuspended in HEPES-BSA buffer (137.5 mM NaCl, 6 mM KCl, 1.25 mM CaCl2, 1.25 mM MgCl2, 
0.4 mM NaH2PO4, 5.6 mM glucose, 10 mM HEPES, BSA (0.1%, w/v), pH 7.4). Cells (100,000 cells/well, 
100μ l) were seeded in black clear bottom 96-well plates (Greiner), and centrifuged at 250 × g for 5 min.
Ligand plates preparation. Two plates (96-well plates, Greiner) were prepared for the screen: one con-
taining test compounds alone in order to determine their direct agonistic activity, and another one 
containing test compounds mixed with CCL17 or CCL22 at room temperature for 1 h (neutraligand 
protocol). The chemokines and test compounds were prepared at a 3× concentration, while digitonin 
was prepared at a 4× concentration. The CCR4 antagonist, C-021 served as control in the experiment. 
In the antagonist protocol, compounds were added to the cell plate (one compound per well) and incu-
bated with cells for 30 min at room temperature, while the agonist (CCL17 or CCL22) was added to the 
ligand plate only.
Recording calcium responses in Indo-1 loaded CCR4+ Gqi5+ HEK cells. Dye loaded cells were placed 
in the FlexStation 3 (Molecular Devices). Calcium mobilization was measured at 401 and 475 nm emis-
sion fluorescence after excitation at 355 nm. For the primary screening, the ligands (50μ l of chemokine 
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mixed with DMSO or test compounds) were added to the cells at 40 s, followed by digitonin addition 
(50μ l) at 100 s to the cells. Molecules were screened at a final concentration of 2μ g/ml with 5 nM CCL17 
or CCL22. DMSO final concentration did not exceed 1% on cells. Raw fluorescence data (at 401 and 
475 nm) were exported and the ratio 401/475 was calculated. The calcium response values (height of 
peak response over baseline) were determined. Hits were selected by comparing the response amplitude 
at the time of the chemokine addition ± test compound. The Z’ factor29 was calculated according to 
the following equation: Z’ = 1-(3SD+ + 3SD−)/|Ave+ − Ave−|, where SD+ and Ave+ are respectively the 
standard deviation and the mean value of the positive controls (chemokine + DMSO), while SD− and 
Ave− are respectively the standard deviation and the mean value of the negative controls (HEPES-BSA 
(0.1%) mixed with DMSO, or cells mixed with C-021). Hit molecules were confirmed by performing 
concentration-response curves and their half maximal inhibitory concentration (IC50) values were cal-
culated using the Kaleidagraph software.
Tryptophan fluorescence assay. Fluorescence measurements were performed on a spectrofluorom-
eter (JobinYvon/Spex) in a quartz microcuvette at 20 °C. CCL17 and CCL22 (1.5 μ M in HEPES buffer 
without BSA) were excited at 285 nm and emission spectra were recorded (300–400 nm). Initial fluo-
rescence intensities (F0) of CCL17 or CCL22 alone were acquired at 340 nm, followed by subsequent 
readings (relative fluorescence, F) after sequential addition of 1μ l of compounds (GPN279 or GPN136 
or C-021 in DMSO) or DMSO alone. The fluorescence emission spectra were corrected by subtracting 
the emission scan of the compounds alone and data analysis was carried out with fluorescence intensities 
detected at 340 nm.
Molecular modeling studies. Molecular modeling was performed with Sybyl-X 2.1 from Tripos 
(now Certara) except otherwise mentioned.
CCL22 Homology modeling. CCL17 was chosen as a template structure to build CCL22 model. Human 
CCL17 structure is available in PDB (PDB code: 1NR4). Human CCL17 and CCL22 primary sequences 
were retrieved from www.uniprot.org website (Accession number: Q92583 - CCL17_HUMAN & O00626 - 
CCL22_HUMAN respectively). ClustalW49 as implemented on the server NPS@50 was used to align both 
sequences. Then the module Orchestrar of the Sybyl package was used to build the CCL22 3D structure 
based on CCL17 (parameters are default one: find and build the conserved regions of chemokines, add 
loops, model side-chains and minimize the internal energy of the modeled structure to release constraints).
Docking studies. Docking studies were performed with Surflex-dock51 as implemented in the Sybyl 
package. We used the default parameters and docking mode “GeomX” to obtain 20 conformations for 
each neutraligand. The “protomol” (which defines the docking site) was defined according to the iden-
tified binding sites.
EGFP-CCR4 receptor internalization. EGFP-CCR4+ HEK cells (1 × 106 cells/ml) were suspended 
in HEPES-BSA (0.1%), and were treated with DMSO or with 100 nM CCL17 or CCL22 in the presence 
of increasing concentrations of GPN279 and GPN136 for 30 min at 37 °C. CCR4 levels were evaluated 
by flow cytometry (FACSCalibur, BD biosciences) using cell surface labeling of EGFP with monoclo-
nal mouse anti-GFP (Roche Applied Science; 1:100 dilution) as primary antibody and R-phycoerythrin 
conjugated AffiniPure F (ab’)2 fragment goat anti-mouse (Immunotech; 1/100) as secondary antibody.
Chemotaxis assay. The T- cell line, HUT78 (ATCC), was cultured in RPMI 1640 supplemented 
with streptomycin, penicillin and 10% FCS without phenol red. Cell migration was carried out in 
RPMI1640-BSA (0.1%) using Transwell 96-well plates (Corning Costar, 5 μ m pore size, polycarbonate 
membranes). CCR4+ HUT78 cells were labeled with calcein AM (Molecular Probe, Invitrogen), 
re-suspended at 2 × 106/ml in RPMI 1640-BSA (0.1%) and placed in the upper wells of the Transwell 
plate. Lower wells contained the same medium diluted with DMSO or chemokine (3 nM CCL17 or 
CCL22). In inhibition studies, chemokines were pre-incubated with various concentrations of com-
pounds (GPN279 or GPN136) in the lower compartment. After a 2 h incubation at 37 °C and 5%CO2, 
the plates were read with an excitation wavelength of 485 nm and an emission wavelength of 535 nm.
Mouse model of allergic eosinophilic airway inflammation (21 days). Nine week-old male Balb/c 
mice (Janvier) were sensitized on days 1 and 7 by intraperitoneal injection of ovalbumin (OVA, 50μ g, 
grade V, Sigma-Aldrich) adsorbed on aluminium hydroxide (2 mg, Sigma-Aldrich) in PBS. Mice were 
challenged intranasally with OVA (10 μ g) in 25μ l of saline on days 18–21. Control mice received intra-
nasal administrations of saline alone. Mice received GPN279 or GPN136 (350 μ mol/Kg) in suspension in 
1% carboxymethylcellulose (CMC, Sigma-Aldrich) or vehicle (1% CMC) administered intraperitoneally 
2 h before each saline or OVA challenge. Animal experimentation was approved by the local ethics com-
mittee (Comité Régional d’Ethique en Matière d’Expérimentation Animale de Strasbourg CREMEAS) 
and carried out in accordance with the approved guidelines. Collection of the bronchoalveolar lavage 
fluid (BALF) was performed 24 h after the last OVA challenge as described previously52. Cell counts 
were assessed by flow cytometry (LSRII® cytometer, BD bioscience). BAL cells were added with FCblock 
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(5 μ l, 553142, BD bioscience) in a black microplate, incubated for 20 min at room temperature. Then, 
marker antibodies were added: CD11c-FITC (557400, BD bioscience), Gr-1-Pe-eFluor610 (61-5931-82, 
eBioscience), CD11b-APC-Cy7 (557657, BD bioscience), CD45-AlexaFluor700 (103128, BioLegend), 
CD3-BV605 (564009, BD bioscience), CD4-PerCP-Cy5.5 (45-0042-82, eBioscience), F4/80-PE (12-4801-
82, eBioscience). Antibodies were incubated for 30 min before DAPI (5 μ l, BD bioscience) addition, and 
flow cytometry was performed immediately.
Statistics. Data from in vitro studies were presented as means ± standard deviation (SD), and were 
analyzed using unpaired two-tailed Student’s t tests (StatView software). *p < 0.05; **p < 0.01; ***p < 0.005. 
Data from in vivo studies were presented as means ± standard error of the mean (SEM) (n = 3–6/group). 
Data were statistically analyzed by one-way ANOVA followed by Tukey’s post-test conducted with Prism 
software (GraphPad). ## p ≤ 0.01; ### p ≤ 0.001 vs solvent group, and *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 
vs OVA group.
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